Veru (NASDAQ:VERU) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a report released on Saturday.
According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “
Other equities analysts have also recently issued research reports about the company. HC Wainwright set a $5.00 price target on Veru and gave the stock a “buy” rating in a research note on Thursday, December 14th. ValuEngine cut Veru from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st.
ILLEGAL ACTIVITY WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2018/01/08/veru-veru-stock-rating-lowered-by-zacks-investment-research.html.
Veru Company Profile
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
What are top analysts saying about Veru? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Veru and related companies.